Singapore markets closed

Straits Times Index
3,297.55
-26.98(-0.81%)
Nikkei
38,814.56
+94.09(+0.24%)
Hang Seng
17,941.78
-170.85(-0.94%)
FTSE 100
8,146.86
-16.81(-0.21%)
Bitcoin USD
66,086.15
+260.67(+0.40%)
CMC Crypto 200
1,398.50
-19.37(-1.37%)

BMY Jul 2024 65.000 put

OPR - OPR Delayed price. Currency in USD

Add to watchlist

23.10

0.00

(0.00%)

At close: 02:09PM EDT

Zacks
Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Augtyro
The FDA approves Bristol Myers' (BMY) cancer drug Augtyro for the treatment of adult and pediatric patients aged 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.
Business Wire
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
PRINCETON, N.J., June 13, 2024--U.S. FDA Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive....
Zacks
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.